S100B(ββ) is also a clinically validated marker for malignant melanoma (elevated only in tumours), traumatic brain injury (TBI) [19,20,21,22,23] and has been associated with cancer progression in multiple myeloma, NSCLC/SCLC and pancreatic cancer [24,25,26,27,28]. This evidence concerns the gene S100B and familial pancreatic carcinoma.